News | February 20, 2013

FDA Committee Recommends Approval of Guerbet’s Macrocyclic, Ionic Gadolinium MRI Contrast Agent

Dotarem Guebert LLC FDA NDA Approval Contrast Media MRI Systems

February 20, 2013 — Guerbet announced that the Medical Imaging Drugs Advisory Committee to U.S. Food and Drug Administration (FDA) has voted unanimously by votes of 17 to zero to recommend that FDA approve the New Drug Application (NDA) for Dotarem (gadoterate meglumine) for adults, and for pediatric use for children two years of age and older. The committee voted 10 to six (with one member abstaining) not to recommend at this time approval of the indication for children under two years of age.

Dotarem is the only macrocyclic and ionic gadolinium-based contrast agent (GBCA) for the intravenous use with magnetic resonance imaging (MRI) in the brain (intracranial), spine and associated tissues in adults and pediatric patients to detect and visualize areas with disruption of the blood-brain barrier (BBB) and/or abnormal vascularity. The Guerbet NDA recommended dose is 0.1 mmol Gd/kg.

"Guerbet is very pleased with the Advisory Committee's recommendation to approve Dotarem based on our comprehensive presentation of clinical and post-marketing data," said Yves L'Epine, CEO of Guerbet Group. "If approved by FDA, we believe Dotarem can provide another CNS imaging option for U.S. clinicians. We are disappointed that the recommendation does not include the indication for children under two years of age, but we take the committee's comments very seriously and will work to address all FDA questions and concerns."

The Dotarem data presented at today's advisory committee meeting included results from two well-controlled Phase III clinical studies. These studies evaluated the diagnostic efficacy of Dotarem in magnetic resonance imaging of diseases of the central nervous system, such as primary or secondary tumors of the brain or spinal cord, inflammatory diseases such as multiple sclerosis and vascular brain diseases.

Both studies evaluated the superiority of the enhanced images over the unenhanced images for central nervous system (CNS) lesion visualization in all three co-primary endpoints. All defined primary and key secondary efficacy analyses were met and support the efficacy of Dotarem® at a standard dose of 0.1 mmol/kg BW. In addition to these two studies, 21 supportive clinical studies evaluated the efficacy of Dotarem-enhanced MRI.

Efficacy of Dotarem in the CNS indication for the pediatric population from zero to 17 years of age was assessed in pivotal study DGD-44-050 and in three open-label, single-group, non-randomized studies (DGD-3-15, DGD-3-16 and DGD-3-29).

MRI has become the mainstay of central nervous system imaging since its introduction over 20 years ago. It is estimated that there were more than 10 million contrast enhanced MRI examinations performed in the United States in 2011, with approximately 60 percent of these examinations performed to image the CNS.

The New Drug Application for gadoterate meglumine was submitted to the FDA on Sept. 20, 2012 and received priority review due to no other GBCA's being approved for children zero to two years of age. The Advisory Committee's recommendations are not binding, but FDA reviewers will consider the panel's recommendation in the final assessment of the NDA.

For more information: www.guerbet.com

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Toshiba Showcases MRI Workflow Enhancements at RSNA 2017
News | Magnetic Resonance Imaging (MRI)| September 21, 2017
September 21, 2017 — Toshiba Medical will highlight its latest...
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media| September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
GE Healthcxare Signa Pioneer MAGIC six contrasts in one scan software by SyntheticMR.

The MRI software enables several different contrasts to be obtained from one scan, shortening scan times.

Feature | Magnetic Resonance Imaging (MRI)| August 31, 2017
August 31, 2017 — The U.S. Food and Drug Administration (FDA) has granted market clearance for SyntheticMR’s SyMRI.
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media| August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Cardiac Imaging| August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Magnetic Resonance Imaging (MRI)| August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
GE Healthcare's Signa Premier MRI Receives FDA 510(k) Clearance
Technology | Magnetic Resonance Imaging (MRI)| August 04, 2017
GE Healthcare announced Signa Premier, a new wide bore 3.0T magnetic resonance imaging (MRI) system, is now available...
Cardiac CT scan showing plaque and calcification in the coronary arteries, from a Toshiba CT scanner
News | Business| July 19, 2017
July 19, 2017 — The Society of Cardiovascular Computed Tomography (SCCT) created a reimbursement fee chart for cardia
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media| July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
Overlay Init